Leukotriene Pathway Activation Associates with Poor Glycemic Control and with Cardiovascular Autonomic Neuropathy in Type 1 Diabetes
Table 2
Demographic, clinical, and biochemical characteristics of type 1 diabetes individuals sorted into the two subgroups shown in Figures 3(a) and 3(b).
Type 1 diabetes patients
value
Group A ()
Group B ()
Clinical and biochemical characteristics
Age (year)
33 (22–42.7)
35 (26.7–39)
NS
Sex, female (%)
62.5
61.4
NS
BMI (kg/m2)
24.0 (21.9–26.8)
25.3 (22.8–27.9)
NS
eGFR (mL·min-1·1.73 m2)
90 (69.5–111)
92 (72–107)
NS
Arterial hypertension (%)
31.2
35.7
NS
Total cholesterol (mg·dL-1)
166 (147–185)
164 (147–187)
NS
(mmol·L-1)
4.3 (3.8–4.8)
4.2 (3.8–4.8)
Triglycerides (mg·dL-1)
80 (56–109)
79 (56–93)
NS
(mmol·L-1)
0.9 (0.6–1.2)
0.89 (0.6–1.0)
Diabetes status
Diabetes duration (years)
20 (15–27)
20 (13.7–28)
NS
Age at diagnosis (years)
12 (8–19)
12 (6–17.5)
NS
HbA1C (%)
7.9 (7.1–9.3)
8.6 (8.1–9.8)
0.01
(mmol·mol-1)
63.5 (54.2–78.1)
71.1 (64.9–83.4)
Fructosamine (μmol·L-1)
369 (310–434)
408 (359–479)
0.02
Microvascular complications
Retinopathy (%)
70.6
65.9
NS
Nephropathy (%)
30
27.3
NS
Peripheral neuropathy (%)
40
40.3
NS
Cardiovascular autonomic neuropathy (%)
43.3
54.5
NS
Use of medicines
ACEI (%)
31.9
18.1
NS
Statin (%)
36.4
45.5
NS
Oxidative markers
GSH (μ·nmol·mL-1)
1.05 (0.86–1.42)
0.88 (0.65–1.04)
<0.0001
TBARS (nmol·mL-1)
2.17 (1.41–6.18)
3.64 (2.20–4.90)
NS
LTB4 (mg·mL-1)
76.3 (60.2–105.7)
116.7 (95.3–139.3)
<0.0001
Data are expressed as . ACEI: angiotensin-converting enzyme inhibitors; BMI: body mass index; eGFR: estimated glomerular filtration rate; GSH: reduced glutathione; TBARS: thiobarbituric acid-reactive substances.
